Cardionovum® Poised for Rapid Commercialization of Its Drug-Coated Balloons (DCB) and Drug-Eluting Stents (DES) in 57 Countries Outside of U.S.

Published: Oct 09, 2012

BONN, Germany--(BUSINESS WIRE)--Cardionovum GmbH announced today that it has established its distribution network in 57 countries since the beginning of 2012.

The Company is commercializing its CE-marked Paclitaxel-coated drug-coated balloon (DCB) for (1) coronary (PRIMUS®) and (2) peripheral (LEGFLOW®) applications since March 2012. Additionally, Cardionovum expects to launch before year-end a next-generation Sirolimus-eluting coronary stent system—PROLIMUS® Biograde, whose design combines proven pro-healing features to promote early re-endothelialization.

Back to news